Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 7/20 | 0.48 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.46 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 9/20 | 0.50 |
| ▸ | HTR2B | P41595 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL174597 | 0.94 | MLNR (0.52) | MLNRHTR2CHTR2BCYP2D6HTR2A | |
| SCHEMBL162032 | 0.87 | HTR2C (0.57) | MLNRHTR2CHTR2BCYP2D6HTR2A | |
| Bromide SCHEMBL174563 | 0.85 | HTR2C (0.55) | MLNRHTR2CHTR2BCYP2D6HTR2A | |
| Malonic Acid SCHEMBL173339 | 0.85 | HTR2C (0.45) | MLNRHTR2CHTR2BCYP2D6HTR2A | |
| Phosphoric Acid SCHEMBL174207 | 0.84 | HTR2C (0.47) | MLNRHTR2CHTR2BCYP2D6HTR2A | |
| Nitric Acid SCHEMBL174071 | 0.82 | MLNR (0.47) | MLNRHTR2CHTR2BCYP2D6HTR2A | |
| Glycolic Acid SCHEMBL174349 | 0.82 | HTR2C (0.45) | MLNRHTR2CHTR2BCYP2D6HTR2A | |
| Succinic Acid SCHEMBL174914 | 0.82 | HTR2C (0.45) | MLNRHTR2CHTR2BCYP2D6HTR2A | |
| Adipic Acid SCHEMBL173690 | 0.79 | HTR2C (0.42) | MLNRHTR2CHTR2BCYP2D6HTR2A | |
| SCHEMBL10623977 | 0.76 | PNMT (0.73) | HTR2CHTR2BHTR6PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |